Vitrakvi
E561039
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Vitrakvi canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6003731 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Vitrakvi Context triple: [Loxo Oncology, leadProductMarketedName, Vitrakvi]
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Vitrakvi Target entity description: Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| hasActiveIngredient | larotrectinib NERFINISHED ⓘ |
| hasAdministrationSchedule | twice daily dosing ⓘ |
| hasApprovalType | tumor-agnostic indication ⓘ |
| hasATCCode | L01EX09 NERFINISHED ⓘ |
| hasBlackBoxWarning | neurotoxicity (region-specific, if applicable) ⓘ |
| hasBrandOwner | Bayer NERFINISHED ⓘ |
| hasCoDeveloper | Bayer NERFINISHED ⓘ |
| hasCommonAdverseEffect |
dizziness
ⓘ
fatigue ⓘ increased liver enzymes ⓘ nausea ⓘ vomiting ⓘ |
| hasDeveloper | Loxo Oncology NERFINISHED ⓘ |
| hasDosageForm |
capsule
ⓘ
oral solution ⓘ |
| hasDrugInteraction |
strong CYP3A4 inducers
ⓘ
strong CYP3A4 inhibitors ⓘ |
| hasFirstApprovalYear | 2018 ⓘ |
| hasIndication |
treatment of metastatic NTRK gene fusion–positive solid tumors
ⓘ
treatment of unresectable NTRK gene fusion–positive solid tumors ⓘ |
| hasInternationalNonproprietaryName | larotrectinib NERFINISHED ⓘ |
| hasMechanismOfAction | selective TRK inhibitor ⓘ |
| hasMolecularTarget | tropomyosin receptor kinases ⓘ |
| hasPediatricUse | yes ⓘ |
| hasPregnancyCategory | may cause fetal harm ⓘ |
| hasRegulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSelectivity | highly selective for TRK proteins ⓘ |
| isIndicatedWhen |
disease has progressed following prior treatment
ⓘ
no satisfactory alternative treatment options ⓘ |
| isMetabolizedBy | CYP3A4 NERFINISHED ⓘ |
| isOralMedication | true ⓘ |
| isTumorAgnostic | true ⓘ |
| isUsedIn | precision oncology ⓘ |
| requiresDiagnosticTest | NTRK gene fusion testing ⓘ |
| targets |
TRKA
NERFINISHED
ⓘ
TRKB NERFINISHED ⓘ TRKC NERFINISHED ⓘ |
| targetsGeneFusion |
NTRK1
NERFINISHED
ⓘ
NTRK2 NERFINISHED ⓘ NTRK3 ⓘ |
| treats |
adult patients with NTRK gene fusion–positive solid tumors
ⓘ
pediatric patients with NTRK gene fusion–positive solid tumors ⓘ solid tumors with NTRK gene fusion ⓘ |
| wasFirstApprovedIn | United States NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Vitrakvi Description of subject: Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology